SciBase: Submits 510(k) to extend Nevisense beyond melanoma in the US - Redeye

SciBase announced this morning that it has submitted a 510(k) premarket notification to the FDA seeking to expand the indication for Nevisense to include non-melanoma skin cancer (keratinocyte skin cancer). We view this as a meaningful milestone that broadens the platform's addressable market and clinical relevance in the company's key growth region.

Länk till analysen i sin helhet: https://www.redeye.se/research/1173101/scibase-submits-510k-to-extend-nevisense-beyond-melanoma-in-the-us?utm_source=finwire&utm_medium=RSS